Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening

Alectinib, also known as Alecensa(®), is prescribed for the therapeutic treatment of individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) who have a specific genetic mutation referred to as anaplastic lymphoma kinase (ALK) positivity. The Food and Drug Administration granted regu...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., AlRabiah, Haitham, Mostafa, Gamal A. E., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610548/
https://www.ncbi.nlm.nih.gov/pubmed/37896209
http://dx.doi.org/10.3390/pharmaceutics15102449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610548/
https://www.ncbi.nlm.nih.gov/pubmed/37896209
http://dx.doi.org/10.3390/pharmaceutics15102449

Ejemplares similares